Bacterial Infections


Although bacteria like E. Coli are the basis for much modern biological research, certain bacterial diseases in humans–including tuberculosis, trachoma, buruli ulcer, and chlamydia—have been under-studied relative to disease burden. One of the challenges in treating these infections is the rising incidence of drug resistance. New antibiotics are often rendered ineffective, in part because of inappropriate or incorrect use. Bacteria are also able to adapt to, and evade, treatment molecules. This necessitates a constant search for new drug targets, treatments, and precise diagnostics that can determine a bacterial strain’s susceptibility to a particular therapy.

tb
Mycobacterium tuberculosis
(Photo: Tom Alber)

A diverse array of model organisms is used in the search for new antibiotics. The discoveries made studying these microbes can inform researchers’ understandings of other more pathogenic organisms. For example, CEND investigator Dan Portnoy has used experiments with Listeria monocytogenes, an mild intracellular bacterial pathogen, to elucidate the process by which intracellular pathogens move from cell to cell, without being detected by the body’s immune system.

 

 

Manfred Auer, Lawrence Berkeley National Laboratory


Suzanne Fleiszig
, Professor, Vision Science and Optometry, Infectious Diseases & Immunity, Microbiology


Brian Krantz, Professor, Molecular and Cell Biology, Chemistry


Sangwei Lu
, Professor, Infectious Diseases


Hiroshi Nikaido
, Professor, Biochemistry, Molecular Biology


Dan Portnoy
, Professor, Molecular and Cell Biology


Lee Riley
, Professor, Epidemiology, Infectious Disease


Richard Stephens
, Professor, Molecular Epidemiology


Russell Vance
, Professor, Molecular and Cell Biology


Qing Zhong,
Professor, Molecular and Cell Biology

 

© 2009 Henry Wheeler Center for Emerging and Neglected Diseases, All Rights Reserved. Webdesign by Szabo Design